Hasil Pengobatan Adjuvan Tamoxifen pada Pasien Kanker Payudara di RSUP Dr. M. Djamil Padang
DOI:
https://doi.org/10.55175/cdk.v46i12.392Kata Kunci:
Disease-free survival, efek samping, survival rateAbstrak
Kanker payudara merupakan kanker yang paling banyak pada perempuan di dunia. Pada beberapa dekade terakhir, pengobatan adjuvan tamoxifen banyak digunakan. Penelitian ini bertujuan mengevaluasi disease-free survival, survival rate, dan efek samping pengobatan tamoxifen. Penelitian deskriptif retrospektif pada bulan September hingga Desember 2016 di RSUP Dr. M. Djamil Padang menggunakan data sekunder 100 sampel dari rekam medik bagian Bedah Onkologi RSUP Dr. M. Djamil Padang dan data primer melalui wawancara. Analisis dilakukan secara univariat dan metode Kaplan-Meier. Hasil penelitian ini didapatkan kelompok usia terbanyak adalah 50-59 tahun dengan rata-rata 52,3 tahun. Disease-free survival 5 tahun adalah 0,727 dan survival rate 5 tahun adalah 0,777. Efek samping paling banyak adalah hot flush (65%). Terdapat hubungan antara efek samping pengobatan tamoxifen dan disease free survival dengan nilai p=0,001 (p < 0,05) kekuatan hubungan sedang (r=0,376).
Breast cancer is the most commonly diagnosed cancer among women worldwide. For the last few decades, adjuvant tamoxifen is the most preferred therapy. This research aims to evaluate the disease-free survival, survival rate, and side effects of tamoxifen therapy. This retrospective descriptive research was conducted in September until December 2016 at Dr. M. Djamil Padang Hospital using 100 secondary data samples from medical records of Surgical Oncology Dept., Dr. M. Djamil Padang Hospital and primary data through interviews. Univariate analysis and Kaplan-Meier method are used. The result shows that the largest age group is 50-59 years old with average 52.3 years old. The 5-year disease-free survival is 0.727 and 5-year survival rate is 0.777, the most frequent side effect is hot flush (65%). There is medium strength of the relationship (r = 0.376) between side effects of tamoxifen treatment with disease-free survival (p = 0.001 <0.05).
Unduhan
Referensi
Breast. Globocan 2018 [Internet]. 2019. Available from: gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf
Breast cancer. WHO [Internet]. 2019. Available from: https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/
Globocan. Breast cancer; Estimated incidence, mortality, and prevalence worldwide in 2012 [Internet]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. 2011.
Kementerian Kesehatan Republik Indonesia. Hasil riskesdas [Internet] 2013. Available from: http://www.depkes.go.id/resource/download/general/pokok2%20hasil%20riskesdas%202013.pdf. 2011.
Harahap WA. Metilasi promoter gen BRCA1 dan hubungannya dengan faktor prognostik pada kanker payudara sporadik premenopausal etnis Minang. [Disertasi]. 2013.
Febrida M. Kasus kanker payudara, terbanyak di RSUP M Djamil Padang. Liputan 6 [Internet] 2013 April 4 [cited 2016 October 12]. Available from: http: health. liputan6.com/read/552632kasus-kanker-payudara-terbanyak-di-rsup-m-djamil-padang.
Manuaba TW, Haryono SJ, Sukasah C, Swantari NM, Bisono. Payudara. In: Sjamsuhidajat R, Karnadihardja W, PTheddeus P, editors. Buku ajar ilmu bedah SjamsuhidajatDe Jong. 3rd ed. Jakarta: EGC; 2011 .p. 471-97
Khambri D. Peran terapi hormonal pada kanker payudara. Maj Kedokt Andalas 2015; 38:64-73
American Cancer Society. Breast cancer fact and figures [Internet]. 2016. Available from: http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
Jordan VC. Tamoxifen: A most unlikely pioneering medicine. Nat Rev Drugs Discovery. 2003;2:205-13
Suherman SK. Estrogen dan progestin, agonis dan antagonisnya. In: Gan S, Gunawan, editors. Farmakologi dan terapi. 5th Ed. Jakarta: Balai Penerbit: FKUI; 2012.
Schultink A, De Vries HM, Zwart W, Linn SC, Beijnen JH, Huitema ADR. Effects of pharmacogenetics on the pharmacokinetics and pharmacodynamics of tamoxifen. Clin Pharmacokinet. 2015;54:797-810
Norsa’adah B, Rusli BN, Imran AK, Naing I, Winn T. Risk factors of breast cancer in women in Klantan Malaysia. Sing Med J. 2005;46(120):698-705
Li J, Huang Y, Zhang BN, Fan JH, Huang R, Zhang P, et al. Body mass index and breast cancer defined by biological receptor status in pre-menopausal and postmenopausal women: A multicenter study in China. Plos One. 2014;9(1):1-9.
Prawirohardjo S, Wiknjosastro H, Sumaparja S, Saifuddin AB. Ilmu kandungan edisi 3. Jakarta: PT. Bina Pustaka Sarwono Prawirohardjo; 2011
Situmorang ML. Karakteristik penderita kanker payudara yang dirawat inap di RSU Dr. Pringadi Medan tahun 2009-2010 [Skripsi]. Universitas Sumatera Utara; 2102.
Veno J. Housewives form majority of breast cancer sufferers. Borneo Post [Internet]. 2016 October 24 [cited 2016 Dec 27]. Available from: www.theborneopost.com/2016/10/24/housewives-form-majority-of-breast-cancer-sufferers/
Antanova L, Aronson K, Mueller CR. Stress and breast cancer: From epidemiology to molecular biology. Breast Cancer Res. 2011;13:2008
Moorman PG, Jones BA, Milikan RC, Hall IJ, Newman B. Race, anthropometric factors and stage at diagnosis of breast cancer. Am J Epidemiol. 2011;153(3):284-91
Yang Li Heng, Hsin Shun Tseng, Che Lin, Li Sheng Chen, Shou Tung Chen, Shou Jen Kuo, et al. Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor positive low grade breast cancer patients. J Breast Ca 2012;295: 288
Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa Maria CA, Banu Arun, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100:1179-83
Ran Gu, Jia Weijuan, Zeng Yunjie, Rao Nanyan, Hu Yue, Li Shunrong, et al. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone positive breast cancer patients: A retrospective cohort study. BMC Cancer 2012;12:161
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF. Results of ATAC (arimidex, tamoxifen, alone opr ot combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60-2
Fontein, Duveken BY, Seynaeve C, Hille ETM, van de Water W, Putter H, et al. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol. 2013;31:2257-64
Hadji P, Kieback DG, Tams J, Hasenburg A, Ziller M. Correlation of treatment-emergent adverse events and clinical response, to endocrine therapy in early breast cancer: A retrospective analysis of the German cohort TEAM. Ann Oncol. 2012;23: 2566-72
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2019 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
